Blis Technologies claims infection win

Last updated 14:28 18/12/2012

Relevant offers


CentrePort 'plenty big enough' for public listing Christmas spending hopes high, despite economic storm clouds Temporary Jetstar terminal moved into place at New Plymouth Airport MBIE proposes more changes to reduce misuse of Financial Services register Vodafone apologises to fuming customers over internet outage in Wellington Did Coke influence anti-obesity group Global Energy Balance Network? Surge in new jobs sees Bay of Plenty unseat Auckland as strongest region Air New Zealand releases Airband monitoring bracelets for unaccompanied minors Electric car boom boosts coal power demand ANZ, BNZ, Westpac bosses' multi-million pay packets revealed

Struggling biotech Blis Technologies says new Italian research proves that children benefit from one of the company's infection fighting products.

The listed company says independent research study into the effectiveness of BLIS K12 oral cavity probiotic for preventing ear and throat infections in children has been published this month.

Published in the International Journal of General Medicine, an Italian research team demonstrated that with BLIS K12 they could prevent the recurrence of common childhood ear and throat infections, such as otitis media or glue ear and tonsillitis by around 40 per cent and 90 per cent respectively, Blis Technologies said in a statement.

Conducted over three years, 82 children aged between 4-5 years with a history of recurrent ear and throat infection, were recruited for this study to determine the effect of 90 days of treatment with either the BLIS K12 probiotic or a placebo.

Researchers concluded that the administration of the BLIS K12 probiotic to children with a history of recurrent oral streptococcal pathology reduced episodes of streptococcal pharyngeal infections and tonsillitis as well as episodes of acute otitis media.

Chief executive Barry Richardson said the BLIS K12 probiotic had evolved a number of defence mechanisms, which protects it from other invading bacteria, such as those known to cause tonsillitis.

In a recent example of a customer who had a specific condition, which made them very susceptible to oral candidiasis with recurrent episodes every 4-6 weeks. At the direction of a pharmacist they started taking one BLIS K12 lozenge a day back in June and to date, they had remained symptom free.

The Dunedin-based company that has lost significant shareholders funds over its history has name investors including Dunedin investor Tony Offen, a director of Blis Technologies, and Forsyth Barr chairman Eion Edgar.

After a period of decline the company's share price has flattened in recent months. This morning it was trading at 1 cent, giving Blis a capitalisation of $6.69m.

Ad Feedback

- The Press

Special offers

Featured Promotions

Sponsored Content